TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12937238

Group type: EXPERIMENTAL
Intervention: Nutritional status in patients with low dietary protein intake (DPI < 0.8 g/kg body weight/day) and energy intake (DEI < 25 kcal/kg body weight/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Interventional study to increase daily DPI and DEI in LOW group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adequate nutrient intake (DPI ≥ 0.8 g/kg body weight/day and DEI ≥ 25 kcal/kg body weight/day) in CON group
Number of subjects: 27
Study: 10713234

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% gel-forming solution (Timoptol-XE(R))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 9333701

Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (CPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open dorsoventral lavage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaparotomy or scheduled reoperation (Etappenlavage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant medical treatments (TNF alpha and interleukin-1 synthesis inhibitors or antibodies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taurolidine (local and intravenous routes)
Number of subjects: 0
Study: 8324332

Group type: EXPERIMENTAL
Intervention: Cimetidine 50 mg/kg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no cimetidine)
Number of subjects: 12
Study: 3334235

Group type: EXPERIMENTAL
Intervention: Early mobilization using tubigrip support (7-13 days after injury)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group using below-elbow plaster splint (4 weeks)
Number of subjects: 56
Study: 29417363

Group type: EXPERIMENTAL
Intervention: Text-messaging program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 28029266

Group type: EXPERIMENTAL
Intervention: Conventional hyrax appliance (Group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hybrid hyrax appliance anchored on mini-implants (Group B)
Number of subjects: 54
Study: 26125754

Group type: EXPERIMENTAL
Intervention: Dezocine and butorphanol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 40
Study: 24065013

Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 454

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 454
Study: 21920204

Group type: EXPERIMENTAL
Intervention: Methylprednisolone + levobupivacaine + saline (G-M + L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methylprednisolone + saline (G-M)
Number of subjects: 60
Study: 17556007

Group type: EXPERIMENTAL
Intervention: Resistance training of the elbow flexor muscles in the complete range of motion (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training of the elbow flexor muscles in the inner range (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both training groups (group 1 and group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control arm (dominant arm)
Number of subjects: 30
Study: 17056975

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with ropivacaine 0.125% and sufentanil 1.0 microg/mL at 14 mL/h; bolus: 5 mL; lockout time: 15 min
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with morphine 2.0 mg/mL; bolus: 3 mg; lockout time: 15 min
Number of subjects: 58
Study: 14598938

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gemifloxacin and Trovafloxacin
Number of subjects: 28
Study: 10930765

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo‐contrastsonography (HyCoSy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 100
Study: 8874573

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 5 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intramuscular morphine 5 mg
Number of subjects: 61
Study: 8061845

Group type: COMPARATOR
Intervention: 1 mg of spirapril once daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 6 mg of spirapril once daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 12 mg of spirapril once daily
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 24 mg of spirapril once daily
Number of subjects: 171
Study: 2647050

Group type: EXPERIMENTAL
Intervention: 2 g of cefoxitin before operation
Number of subjects: 1735

Group type: COMPARATOR
Intervention: Control group (no prophylaxis mentioned)
Number of subjects: 1735
Study: 30565342

Group type: COMPARATOR
Intervention: Simulated TEAS combined with sertraline (group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Simulated TEAS combined with CBT (group B)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Active TEAS combined with CBT (group C)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Active TEAS combined with CBT plus sertraline (group D)
Number of subjects: 240
Study: 28527821

Group type: EXPERIMENTAL
Intervention: 1% lidocaine buffered with sodium bicarbonate (9:1 ratio)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1% lidocaine alone (control group)
Number of subjects: 85
Study: 25306231

Group type: EXPERIMENTAL
Intervention: burst TENS
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: cryotherapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: cryotherapy in combination with burst TENS
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: cryotherapy in combination with conventional TENS
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: conventional TENS
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: placebo TENS
Number of subjects: 112

Group type: COMPARATOR
Intervention: control
Number of subjects: 112
Study: 23777380

Group type: EXPERIMENTAL
Intervention: Training group (Nordic curl, forward lunges on a Bosu balance trainer, eccentric single leg dead lifts)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 23237643

Group type: EXPERIMENTAL
Intervention: Psychological Inoculation (PI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Health Education (Control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 19681881

Group type: EXPERIMENTAL
Intervention: RCTs published in 2006
Number of subjects: 98

Group type: COMPARATOR
Intervention: RCTs published in 1997
Number of subjects: 98
Study: 17512147

Group type: EXPERIMENTAL
Intervention: Tablet A (swelling/disintegration-type matrix tablet with hydrophobic wax and hydrophilic polymer granules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet B (matrix tablet consisting of hydrophilic polymer granules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet B
Number of subjects: 0
Study: 15448514

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 11504980

Group type: EXPERIMENTAL
Intervention: HAART responders
Number of subjects: 44

Group type: COMPARATOR
Intervention: HAART non-responders
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients with virological or immunological response
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immunological response, higher RDI, CR to chemotherapy
Number of subjects: 44
Study: 9676069

Group type: EXPERIMENTAL
Intervention: Newer Antidepressants (NAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - TCA group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - NTCA-SSRI group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - SSRIs
Number of subjects: 0
Study: 7485207

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg BID
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 2276184

Group type: EXPERIMENTAL
Intervention: DTP vaccine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 6243518

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31876117

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (once-monthly formulation)
Number of subjects: 587
Study: 30576840

Group type: EXPERIMENTAL
Intervention: Culturally relevant smartphone-delivered physical activity intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Culturally relevant wellness attention-matched control condition
Number of subjects: 60
Study: 28476101

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (LSM) using a web-based program (18 individual sessions for 24 weeks)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 420
Study: 26015650

Group type: EXPERIMENTAL
Intervention: Ofloxacin alone (OA) eardrops for 15 days
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ofloxacin + dexamethasone combination (ODC) eardrops for 15 days
Number of subjects: 110
Study: 24183751

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Poor psychosocial functioning
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Greater symptoms of anxiety
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Apathy
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Negative attitudes toward medication
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Medication side effects
Number of subjects: 1437
Study: 21455872

Group type: EXPERIMENTAL
Intervention: 5-Fr pancreatic duct stents
Number of subjects: 78

Group type: COMPARATOR
Intervention: 3-Fr pancreatic duct stents
Number of subjects: 78
Study: 18359313

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DESs)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Bare Metal Stents (BMSs)
Number of subjects: 360
Study: 16490807

Group type: EXPERIMENTAL
Intervention: AST-120 (3 g thrice daily for 2 days) administered 60 minutes after losartan (100 mg) under fed conditions (Treatment C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AST-120 administered 30 minutes prior to losartan (Treatment D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AST-120 administered 30 minutes after losartan (Treatment E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan (100 mg) administered alone under fasting conditions (Treatment A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan (100 mg) administered alone under fed conditions (Treatment B)
Number of subjects: 0
Study: 12880361

Group type: EXPERIMENTAL
Intervention: Thermo-optical behavior measurement using a two-site temperature differential method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Classification algorithm using a discriminant function
Number of subjects: 12
Study: 12167947

Group type: EXPERIMENTAL
Intervention: Crest Multicare Advanced Cleaning dentifrice (polypyrophosphate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Industry standard pyrophosphate dentifrice
Number of subjects: 0
Study: 1816752

Group type: EXPERIMENTAL
Intervention: PADMA‐28 for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 50
Study: 30369394

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching from Gla-100 to Gla-300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of once-daily insulin injections
Number of subjects: 0
Study: 30092651

Group type: EXPERIMENTAL
Intervention: 15° hook plate
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0° hook plate
Number of subjects: 43
Study: 27003376

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behaviour therapy (TD‐CBT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Disorder‐specific cognitive behaviour therapy (DS‐CBT)
Number of subjects: 145
Study: 24378766

Group type: COMPARATOR
Intervention: Ex + PLA (exercise and placebo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ex + ISO (exercise and isoflavones)
Number of subjects: 34
Study: 22803424

Group type: EXPERIMENTAL
Intervention: Hewei Zhiou Recipe (HZR) combined with ondansetron hydrochloride (OH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ondansetron hydrochloride (OH)
Number of subjects: 80
Study: 21629372

Group type: EXPERIMENTAL
Intervention: Above-elbow cast
Number of subjects: 85

Group type: COMPARATOR
Intervention: Below-elbow cast
Number of subjects: 85
Study: 17656275

Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonresorbable multifilament sutures (Supramid, Synthofil, Ethibond Excel, Ti‐cron)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absorbable monofilament Monocryl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonresorbable sutures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absorbable silk and Monocryl
Number of subjects: 60
Study: 16200918

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study: 11825938

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Picornavirus positive patients
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Influenza virus positive patients
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Common respiratory viruses or atypical pathogens
Number of subjects: 719
Study: 10365837

Group type: EXPERIMENTAL
Intervention: Endoscopic Nd:YAG laser treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intratumoural injection of 98% alcohol
Number of subjects: 47
Study: 7736318

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.5 microgram/day) for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro CTR treatment (10(‐7) M) of PBMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro CTR treatment (10(‐7) M) for 48 hours in PBMC from HD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro CTR treatment (10(‐11) and 10(‐9) M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline NK cell activity in HD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment effect on serum levels
Number of subjects: 0
Study: 2407164

Group type: EXPERIMENTAL
Intervention: PCA infusion (Abbott Lifecare)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Traditional postoperative analgesia (intramuscular or intravenous methods)
Number of subjects: 69
Study: 6187790

Group type: EXPERIMENTAL
Intervention: Kallikrein (KK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Compound 48/80
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 40
Study: 30040127

Group type: EXPERIMENTAL
Intervention: ProTaper Next (PN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Reciproc (R)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both interventions (PN and R)
Number of subjects: 58
Study: 30399184

Group type: EXPERIMENTAL
Intervention: Whole of service intervention that diverted people away from hospital and into stepped care psychological therapy clinics
Number of subjects: 642

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 642
Study: 26220327

Group type: EXPERIMENTAL
Intervention: Early rehabilitation with Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Early rehabilitation with Cognitive Therapeutic Exercise (CTE)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Delayed rehabilitation with standard protocol
Number of subjects: 340
Study: 25204862

Group type: EXPERIMENTAL
Intervention: Caretaker mental health measured by the Self‐Reporting Questionnaire‐20 (SRQ‐20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 0
Study: 22971472

Group type: EXPERIMENTAL
Intervention: Comparator (COMP, 100% probability of receiving active medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled (PC, 50% probability of receiving active medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both COMP and PC conditions (active medication)
Number of subjects: 0
Study: 20429673

Group type: EXPERIMENTAL
Intervention: Ospemifene (daily doses)
Number of subjects: 0
Study: 17995971

Group type: EXPERIMENTAL
Intervention: Carvedilol, daily doses of 3 mg kg(‐1) for infants (28 days to 23 months)
Number of subjects: 41
Study: 15669893

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 12957443

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy with bucindolol
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Diabetes presence
Number of subjects: 2708
Study: 10098755

Group type: EXPERIMENTAL
Intervention: Women with non‐metastatic breast cancer at first diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with soft‐tissue metastases without evidence of skeletal metastases
Number of subjects: 0
Study: 10830013

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 93
Study: 1816137

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 329

Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 329
Study: 7136329

Group type: EXPERIMENTAL
Intervention: Metronidazole and Neomycin with low residue diet and orthograde cleaning of the bowel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous regimen (not specified)
Number of subjects: 0
Study: 30573715

Group type: EXPERIMENTAL
Intervention: K+T+A (1 tablet of Ketorolac 10 mg plus 1 capsule of Tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: K (1 tablet of Ketorolac 10 mg plus 1 placebo capsule)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: K+T+A
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: K+T+A and K
Number of subjects: 52
Study: 30365591

Group type: EXPERIMENTAL
Intervention: SB206 12% QD
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SB206 (4% QD, 4% BID, 8% QD, 12% QD)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 108
Study: 27429803

Group type: EXPERIMENTAL
Intervention: Probiotic Mixture (VSL#3)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 24619298

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of sorafenib 400 mg bid with IV carboplatin (AUC 6) and IV paclitaxel 175 mg/m2 (S+C/T) every 3 weeks
Number of subjects: 36
Study: 22395880

Group type: EXPERIMENTAL
Intervention: Clinical signs of infectious keratitis assessed by cornea specialists
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gram stain, genus, and species identification
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Presence of irregular/feathery border
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Presence of wreath infiltrate or epithelial plaque
Number of subjects: 80
Study: 19563257

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (various dosages over 14 days)
Number of subjects: 48
Study: 17720661

Group type: EXPERIMENTAL
Intervention: Darunavir with low-dose ritonavir (DRV/r)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Control PI (almost all ritonavir boosted)
Number of subjects: 697
Study: 15871609

Group type: EXPERIMENTAL
Intervention: Oral diclofenac sodium (50 mg tablets, twice a day for 14 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (16 mg/ml, 10 drops 4 times a day for 14 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 36
Study: 11916233

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 22000
Study: 9723150

Group type: EXPERIMENTAL
Intervention: Sertraline (12 weeks treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (12 weeks treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients with severe pressure hyperalgesia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients with severe non-somatic depressive symptoms
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 21
Study: 7584284

Group type: EXPERIMENTAL
Intervention: Practice at writing target names
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading target names
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More frequent practice trials
Number of subjects: 0
Study: 2508583

Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ENT (Enteral Feedings)
Number of subjects: 12
Study: 826236

Group type: EXPERIMENTAL
Intervention: Glucose only
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amino acids only
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of glucose and amino acids
Number of subjects: 23
Study: 31483662

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Bevacizumab
Number of subjects: 132

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without Bevacizumab
Number of subjects: 132
Study: 28440872

Group type: EXPERIMENTAL
Intervention: Brochure and lay health educator (LHE) outreach (print + LHE)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Brochure (print)
Number of subjects: 348